Neumora stock price target cut to $7 on failed trial, H.C. Wainwright maintains buy
Corroborated by 2 sources from 2 publishers
globalcrime1d ago
TL;DR
Reports differ across sources; according to finance.yahoo.com, today, a brief rundown of news involving Neumora Therapeutics and enGene, as well as updates from Johnson & Johnson, Cellares and Faeth Therapeutics that you may have missed.